Identification of pathways for bipolar disorder: A meta-analysis

Psychiatric Genomics Consortium Bipolar Group

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

IMPORTANCE Genome-wide investigations provide systematic information regarding the neurobiology of psychiatric disorders. OBJECTIVE To identify biological pathways that contribute to risk for bipolar disorder (BP) using genes with consistent evidence for association in multiple genome-wide association studies (GWAS). DATA SOURCES Four independent data sets with individual genome-wide data available in July 2011 along with all data sets contributed to the Psychiatric Genomics Consortium Bipolar Group by May 2012. A prior meta-analysis was used as a source for brain gene expression data. STUDY SELECTION The 4 published GWAS were included in the initial sample. All independent BP data sets providing genome-wide data in the Psychiatric Genomics Consortium were included as a replication sample. DATA EXTRACTION AND SYNTHESIS We identified 966 genes that contained 2 or more variants associated with BP at P < .05 in 3 of 4 GWAS data sets (n = 12 127 [5253 cases, 6874 controls]). Simulations using 10 000 replicates of these data sets corrected for gene size and allowed the calculation of an empirical P value for each gene; empirically significant genes were entered into a pathway analysis. Each of these pathways was then tested in the replication sample (n = 8396 [3507 cases, 4889 controls]) using gene set enrichment analysis for single-nucleotide polymorphisms. The 226 genes were also compared with results from ameta-analysis of gene expression in the dorsolateral prefrontal cortex. MAIN OUTCOMES AND MEASURES Empirically significant genes and biological pathways. RESULTS Among 966 genes, 226 were empirically significant (P < .05). Seventeen pathways were overrepresented in analyses of the initial data set. Six of the 17 pathways were associated with BP in both the initial and replication samples: corticotropin-releasing hormone signaling, cardiac β-adrenergic signaling, phospholipase C signaling, glutamate receptor signaling, endothelin 1 signaling, and cardiac hypertrophy signaling. Among the 226 genes, 9 differed in expression in the dorsolateral prefrontal cortex in patients with BP: CACNA1C, DTNA, FOXP1, GNG2, ITPR2, LSAMP, NPAS3, NCOA2, and NTRK3. CONCLUSIONS AND RELEVANCE Pathways involved in the genetic predisposition to BP include hormonal regulation, calcium channels, second messenger systems, and glutamate signaling. Gene expression studies implicate neuronal development pathways as well. These results tend to reinforce specific hypotheses regarding BP neurobiology and may provide clues for new approaches to treatment and prevention.

Original languageEnglish (US)
Pages (from-to)657-664
Number of pages8
JournalJAMA psychiatry
Volume71
Issue number6
DOIs
StatePublished - Jun 1 2014

Fingerprint

Bipolar Disorder
Meta-Analysis
Genes
Genome-Wide Association Study
Psychiatry
Neurobiology
Genome
Genomics
Prefrontal Cortex
Gene Expression
Gene
Meta-analysis
Pathway
Corticotropin-Releasing Hormone
Glutamate Receptors
Cardiomegaly
Type C Phospholipases
Second Messenger Systems
Endothelin-1
Calcium Channels

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Identification of pathways for bipolar disorder : A meta-analysis. / Psychiatric Genomics Consortium Bipolar Group.

In: JAMA psychiatry, Vol. 71, No. 6, 01.06.2014, p. 657-664.

Research output: Contribution to journalArticle

Psychiatric Genomics Consortium Bipolar Group 2014, 'Identification of pathways for bipolar disorder: A meta-analysis', JAMA psychiatry, vol. 71, no. 6, pp. 657-664. https://doi.org/10.1001/jamapsychiatry.2014.176
Psychiatric Genomics Consortium Bipolar Group. / Identification of pathways for bipolar disorder : A meta-analysis. In: JAMA psychiatry. 2014 ; Vol. 71, No. 6. pp. 657-664.
@article{eba35a689bd44f79aa3c0fa7b8535b36,
title = "Identification of pathways for bipolar disorder: A meta-analysis",
abstract = "IMPORTANCE Genome-wide investigations provide systematic information regarding the neurobiology of psychiatric disorders. OBJECTIVE To identify biological pathways that contribute to risk for bipolar disorder (BP) using genes with consistent evidence for association in multiple genome-wide association studies (GWAS). DATA SOURCES Four independent data sets with individual genome-wide data available in July 2011 along with all data sets contributed to the Psychiatric Genomics Consortium Bipolar Group by May 2012. A prior meta-analysis was used as a source for brain gene expression data. STUDY SELECTION The 4 published GWAS were included in the initial sample. All independent BP data sets providing genome-wide data in the Psychiatric Genomics Consortium were included as a replication sample. DATA EXTRACTION AND SYNTHESIS We identified 966 genes that contained 2 or more variants associated with BP at P < .05 in 3 of 4 GWAS data sets (n = 12 127 [5253 cases, 6874 controls]). Simulations using 10 000 replicates of these data sets corrected for gene size and allowed the calculation of an empirical P value for each gene; empirically significant genes were entered into a pathway analysis. Each of these pathways was then tested in the replication sample (n = 8396 [3507 cases, 4889 controls]) using gene set enrichment analysis for single-nucleotide polymorphisms. The 226 genes were also compared with results from ameta-analysis of gene expression in the dorsolateral prefrontal cortex. MAIN OUTCOMES AND MEASURES Empirically significant genes and biological pathways. RESULTS Among 966 genes, 226 were empirically significant (P < .05). Seventeen pathways were overrepresented in analyses of the initial data set. Six of the 17 pathways were associated with BP in both the initial and replication samples: corticotropin-releasing hormone signaling, cardiac β-adrenergic signaling, phospholipase C signaling, glutamate receptor signaling, endothelin 1 signaling, and cardiac hypertrophy signaling. Among the 226 genes, 9 differed in expression in the dorsolateral prefrontal cortex in patients with BP: CACNA1C, DTNA, FOXP1, GNG2, ITPR2, LSAMP, NPAS3, NCOA2, and NTRK3. CONCLUSIONS AND RELEVANCE Pathways involved in the genetic predisposition to BP include hormonal regulation, calcium channels, second messenger systems, and glutamate signaling. Gene expression studies implicate neuronal development pathways as well. These results tend to reinforce specific hypotheses regarding BP neurobiology and may provide clues for new approaches to treatment and prevention.",
author = "{Psychiatric Genomics Consortium Bipolar Group} and Nurnberger, {John I.} and Koller, {Daniel L.} and Jeesun Jung and Edenberg, {Howard J.} and Tatiana Foroud and Ilaria Guella and Vawter, {Marquis P.} and Kelsoe, {John R.} and Pamela Sklar and Stephan Ripke and Scott, {Laura J.} and Andreassen, {Ole A.} and Sven Cichon and Nick Craddock and Marcella Rietschel and Douglas Blackwood and Aiden Corvin and Matthew Flickinger and Weihua Guan and Morten Mattingsdal and Andrew McQuillin and Phoenix Kwan and Wienker, {Thomas F.} and Mark Daly and Frank Dudbridge and Holmans, {Peter A.} and Danyu Lin and Margit Burmeister and Greenwood, {Tiffany A.} and Hamshere, {Marian L.} and Pierandrea Muglia and Smith, {Erin N.} and Zandi, {Peter P.} and Nievergelt, {Caroline M.} and Rebecca McKinney and Shilling, {Paul D.} and Schork, {Nicholas J.} and Bloss, {Cinnamon S.} and Gershon, {Elliot S.} and Chunyu Liu and Badner, {Judith A.} and Scheftner, {William A.} and Lawson, {William B.} and Nwulia, {Evaristus A.} and Maria Hipolito and William Coryell and John Rice and William Byerley and McMahon, {Francis J.} and Schulze, {Thomas G.}",
year = "2014",
month = "6",
day = "1",
doi = "10.1001/jamapsychiatry.2014.176",
language = "English (US)",
volume = "71",
pages = "657--664",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Identification of pathways for bipolar disorder

T2 - A meta-analysis

AU - Psychiatric Genomics Consortium Bipolar Group

AU - Nurnberger, John I.

AU - Koller, Daniel L.

AU - Jung, Jeesun

AU - Edenberg, Howard J.

AU - Foroud, Tatiana

AU - Guella, Ilaria

AU - Vawter, Marquis P.

AU - Kelsoe, John R.

AU - Sklar, Pamela

AU - Ripke, Stephan

AU - Scott, Laura J.

AU - Andreassen, Ole A.

AU - Cichon, Sven

AU - Craddock, Nick

AU - Rietschel, Marcella

AU - Blackwood, Douglas

AU - Corvin, Aiden

AU - Flickinger, Matthew

AU - Guan, Weihua

AU - Mattingsdal, Morten

AU - McQuillin, Andrew

AU - Kwan, Phoenix

AU - Wienker, Thomas F.

AU - Daly, Mark

AU - Dudbridge, Frank

AU - Holmans, Peter A.

AU - Lin, Danyu

AU - Burmeister, Margit

AU - Greenwood, Tiffany A.

AU - Hamshere, Marian L.

AU - Muglia, Pierandrea

AU - Smith, Erin N.

AU - Zandi, Peter P.

AU - Nievergelt, Caroline M.

AU - McKinney, Rebecca

AU - Shilling, Paul D.

AU - Schork, Nicholas J.

AU - Bloss, Cinnamon S.

AU - Gershon, Elliot S.

AU - Liu, Chunyu

AU - Badner, Judith A.

AU - Scheftner, William A.

AU - Lawson, William B.

AU - Nwulia, Evaristus A.

AU - Hipolito, Maria

AU - Coryell, William

AU - Rice, John

AU - Byerley, William

AU - McMahon, Francis J.

AU - Schulze, Thomas G.

PY - 2014/6/1

Y1 - 2014/6/1

N2 - IMPORTANCE Genome-wide investigations provide systematic information regarding the neurobiology of psychiatric disorders. OBJECTIVE To identify biological pathways that contribute to risk for bipolar disorder (BP) using genes with consistent evidence for association in multiple genome-wide association studies (GWAS). DATA SOURCES Four independent data sets with individual genome-wide data available in July 2011 along with all data sets contributed to the Psychiatric Genomics Consortium Bipolar Group by May 2012. A prior meta-analysis was used as a source for brain gene expression data. STUDY SELECTION The 4 published GWAS were included in the initial sample. All independent BP data sets providing genome-wide data in the Psychiatric Genomics Consortium were included as a replication sample. DATA EXTRACTION AND SYNTHESIS We identified 966 genes that contained 2 or more variants associated with BP at P < .05 in 3 of 4 GWAS data sets (n = 12 127 [5253 cases, 6874 controls]). Simulations using 10 000 replicates of these data sets corrected for gene size and allowed the calculation of an empirical P value for each gene; empirically significant genes were entered into a pathway analysis. Each of these pathways was then tested in the replication sample (n = 8396 [3507 cases, 4889 controls]) using gene set enrichment analysis for single-nucleotide polymorphisms. The 226 genes were also compared with results from ameta-analysis of gene expression in the dorsolateral prefrontal cortex. MAIN OUTCOMES AND MEASURES Empirically significant genes and biological pathways. RESULTS Among 966 genes, 226 were empirically significant (P < .05). Seventeen pathways were overrepresented in analyses of the initial data set. Six of the 17 pathways were associated with BP in both the initial and replication samples: corticotropin-releasing hormone signaling, cardiac β-adrenergic signaling, phospholipase C signaling, glutamate receptor signaling, endothelin 1 signaling, and cardiac hypertrophy signaling. Among the 226 genes, 9 differed in expression in the dorsolateral prefrontal cortex in patients with BP: CACNA1C, DTNA, FOXP1, GNG2, ITPR2, LSAMP, NPAS3, NCOA2, and NTRK3. CONCLUSIONS AND RELEVANCE Pathways involved in the genetic predisposition to BP include hormonal regulation, calcium channels, second messenger systems, and glutamate signaling. Gene expression studies implicate neuronal development pathways as well. These results tend to reinforce specific hypotheses regarding BP neurobiology and may provide clues for new approaches to treatment and prevention.

AB - IMPORTANCE Genome-wide investigations provide systematic information regarding the neurobiology of psychiatric disorders. OBJECTIVE To identify biological pathways that contribute to risk for bipolar disorder (BP) using genes with consistent evidence for association in multiple genome-wide association studies (GWAS). DATA SOURCES Four independent data sets with individual genome-wide data available in July 2011 along with all data sets contributed to the Psychiatric Genomics Consortium Bipolar Group by May 2012. A prior meta-analysis was used as a source for brain gene expression data. STUDY SELECTION The 4 published GWAS were included in the initial sample. All independent BP data sets providing genome-wide data in the Psychiatric Genomics Consortium were included as a replication sample. DATA EXTRACTION AND SYNTHESIS We identified 966 genes that contained 2 or more variants associated with BP at P < .05 in 3 of 4 GWAS data sets (n = 12 127 [5253 cases, 6874 controls]). Simulations using 10 000 replicates of these data sets corrected for gene size and allowed the calculation of an empirical P value for each gene; empirically significant genes were entered into a pathway analysis. Each of these pathways was then tested in the replication sample (n = 8396 [3507 cases, 4889 controls]) using gene set enrichment analysis for single-nucleotide polymorphisms. The 226 genes were also compared with results from ameta-analysis of gene expression in the dorsolateral prefrontal cortex. MAIN OUTCOMES AND MEASURES Empirically significant genes and biological pathways. RESULTS Among 966 genes, 226 were empirically significant (P < .05). Seventeen pathways were overrepresented in analyses of the initial data set. Six of the 17 pathways were associated with BP in both the initial and replication samples: corticotropin-releasing hormone signaling, cardiac β-adrenergic signaling, phospholipase C signaling, glutamate receptor signaling, endothelin 1 signaling, and cardiac hypertrophy signaling. Among the 226 genes, 9 differed in expression in the dorsolateral prefrontal cortex in patients with BP: CACNA1C, DTNA, FOXP1, GNG2, ITPR2, LSAMP, NPAS3, NCOA2, and NTRK3. CONCLUSIONS AND RELEVANCE Pathways involved in the genetic predisposition to BP include hormonal regulation, calcium channels, second messenger systems, and glutamate signaling. Gene expression studies implicate neuronal development pathways as well. These results tend to reinforce specific hypotheses regarding BP neurobiology and may provide clues for new approaches to treatment and prevention.

UR - http://www.scopus.com/inward/record.url?scp=84902204761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902204761&partnerID=8YFLogxK

U2 - 10.1001/jamapsychiatry.2014.176

DO - 10.1001/jamapsychiatry.2014.176

M3 - Article

C2 - 24718920

AN - SCOPUS:84902204761

VL - 71

SP - 657

EP - 664

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 6

ER -